Breast cancer pathway (Homo sapiens)
From WikiPathways
Description
Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland.
The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include:
* Luminal A subtype: Hormone receptor positive (progesterone and estrogen) and HER2 (ERBB2) negative
* Luminal B subtype: Hormone receptor positive (progesterone and estrogen) and HER2 (ERBB2) positive
* HER2 positive: Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2) positive
* Basal-like or triple-negative (TNBCs): Hormone receptor negative (progesterone and estrogen) and HER2 (ERBB2) negativeHormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumors, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signaling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers. Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org.
Quality Tags
 | Approved version |
 | Community: CPTAC |
 | Annotate nodes |
 |  |
Ontology Terms
Saving...Pathway Ontology : phosphatidylinositol 3-kinase-Akt signaling pathway breast cancer pathway Notch signaling pathway cancer pathway disease pathway
Disease : cancer
Bibliography
View all... |
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL; ''Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.''; Science, 1987 PubMed Europe PMC Scholia
- Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ; ''Activating HER2 mutations in HER2 gene amplification negative breast cancer.''; Cancer Discov, 2013 PubMed Europe PMC Scholia
- Mukohara T; ''PI3K mutations in breast cancer: prognostic and therapeutic implications.''; Breast Cancer (Dove Med Press), 2015 PubMed Europe PMC Scholia
- Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R; ''PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.''; Cancer Res, 2005 PubMed Europe PMC Scholia
- Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, Gatza ML, Wilkerson M, Perou CM, Yellapantula V, Huang KL, Lin C, McLellan MD, Yan P, Davies SR, Townsend RR, Skates SJ, Wang J, Zhang B, Kinsinger CR, Mesri M, Rodriguez H, Ding L, Paulovich AG, Fenyö D, Ellis MJ, Carr SA; ''Proteogenomics connects somatic mutations to signalling in breast cancer.''; Nature, 2016 PubMed Europe PMC Scholia
- O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR; ''Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.''; Clin Cancer Res, 2010 PubMed Europe PMC Scholia
- Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT; ''An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.''; Cancer Res, 2008 PubMed Europe PMC Scholia
- Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L; ''Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.''; Nat Commun, 2017 PubMed Europe PMC Scholia
- Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E; ''PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.''; Nucleic Acids Res, 2015 PubMed Europe PMC Scholia
- Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS; ''FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.''; Breast Cancer Res, 2007 PubMed Europe PMC Scholia
- Hynes NE, Dey JH; ''Potential for targeting the fibroblast growth factor receptors in breast cancer.''; Cancer Res, 2010 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
Annotated Interactions
No annotated interactions
